GeneDx Holdings Corp. (WGS) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $44.73: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Below long-term trend.
GeneDx provides exome and whole genome sequencing primarily for pediatric rare disease diagnosis, backed by one of the world's largest rare disease datasets (GeneDx Infinity™, 2.5M+ tests). Nearly all 2025 revenue was from diagnostic test reports reimbursed by third-party... Read more
Sell if holding. Engine safety override at $44.73: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Below long-term trend. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.8/10, moderate confidence.
Passes 7/10 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 69d clear, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — GeneDx Holdings Corp.
Latest news
- Insider sells Class A stock at WGS (NASDAQ: WGS) — multiple lots reported - Stock Titan — Stock Titan negative
- Earnings Preview: WGS to Report Financial Results Post-market on May 04 - Moomoo — Moomoo neutral
- Jefferies reiterates GeneDx stock rating citing market penetration - Investing.com — Investing.com positive
- WGS Stock Slumps After Hours As Firm Predicts Lower Test Volume For Year - Stocktwits — Stocktwits negative
- Craig-Hallum reaffirms buy on GeneDx (WGS) with $153 price target - MSN — MSN positive
Generated 2026-05-21T00:46:27Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierlimited number of suppliers10-K Item 1: 'We rely on a limited number of suppliers, including Illumina, Inc., Life Technologies Corporation, Twist Biosciences Corporation, Path-Tec LLC and Agilent Technologies. for certain laboratory reagents'
Material Events(8-K, last 90d)
- 2026-03-02Item 1.02MEDIUMGeneDx terminated its existing credit agreement with Perceptive Credit Holdings IV, LP on February 27, 2026 upon entering a new $100M term loan with Blackstone. Perceptive facility repaid in full.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Unprofitable operations — net margin -17.6%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $44.73: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Below long-term trend. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $41.60. Score 5.8/10, moderate confidence.
Take-profit target: $66.99 (+49.8% upside). Prior stop was $41.60. Stop-loss: $41.60.
Concentration risk — Supplier: limited number of suppliers; Quality below floor (3.9 < 4.0).
GeneDx Holdings Corp. trades at a P/E of N/A (forward 34.2). TrendMatrix value score: 7.8/10. Verdict: Sell.
13 analysts cover WGS with a consensus score of 4.2/5. Average price target: $77.
What does GeneDx Holdings Corp. do?GeneDx provides exome and whole genome sequencing primarily for pediatric rare disease diagnosis, backed by one of the...
GeneDx provides exome and whole genome sequencing primarily for pediatric rare disease diagnosis, backed by one of the world's largest rare disease datasets (GeneDx Infinity™, 2.5M+ tests). Nearly all 2025 revenue was from diagnostic test reports reimbursed by third-party payors; ~1.5% of revenues are from outside the U.S. The proprietary dataset creates a diagnostic flywheel—each new test improves interpretation accuracy.